Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs

Mark Alles

→ For the first time since he sold Celgene to Bristol Myers Squibb for $74 billion in 2019, Mark Alles is a CEO again. Alles had been chairing the board at TORL Biotherapeutics, an antibody maker from UCLA’s Dennis Slamon, and will now…
Click here to view original post